FI122520B - Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena - Google Patents

Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena Download PDF

Info

Publication number
FI122520B
FI122520B FI20106067A FI20106067A FI122520B FI 122520 B FI122520 B FI 122520B FI 20106067 A FI20106067 A FI 20106067A FI 20106067 A FI20106067 A FI 20106067A FI 122520 B FI122520 B FI 122520B
Authority
FI
Finland
Prior art keywords
rotavirus
norovirus
antigen
vaccine
vlp
Prior art date
Application number
FI20106067A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI20106067A0 (fi
Inventor
Vesna Blazevic
Timo Vesikari
Kirsi Nurminen
Leena Huhti
Suvi Lappalainen
Eeva Jokela
Original Assignee
Vesna Blazevic
Timo Vesikari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vesna Blazevic, Timo Vesikari filed Critical Vesna Blazevic
Publication of FI20106067A0 publication Critical patent/FI20106067A0/fi
Priority to FI20106067A priority Critical patent/FI122520B/fi
Priority to US13/269,326 priority patent/US8895015B2/en
Priority to AU2011315405A priority patent/AU2011315405B2/en
Priority to SG2013027974A priority patent/SG189398A1/en
Priority to PCT/FI2011/050880 priority patent/WO2012049366A1/en
Priority to CA2814175A priority patent/CA2814175C/en
Priority to EP11832191.8A priority patent/EP2627353B1/en
Priority to MX2013004159A priority patent/MX352478B/es
Priority to BR112013009164A priority patent/BR112013009164A2/pt
Priority to KR1020137012218A priority patent/KR101847472B1/ko
Priority to RU2013121815/10A priority patent/RU2013121815A/ru
Priority to CN201180049612.4A priority patent/CN103260645B/zh
Priority to JP2013533249A priority patent/JP5902181B2/ja
Priority to TW100137092A priority patent/TWI479022B/zh
Application granted granted Critical
Publication of FI122520B publication Critical patent/FI122520B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI20106067A 2010-10-14 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena FI122520B (fi)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FI20106067A FI122520B (fi) 2010-10-15 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
US13/269,326 US8895015B2 (en) 2010-10-14 2011-10-07 Norovirus capsid and rotavirus VP6 protein for use as combined vaccine
EP11832191.8A EP2627353B1 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine
KR1020137012218A KR101847472B1 (ko) 2010-10-14 2011-10-12 혼합 백신으로 사용하기 위한 노로바이러스 캡시드 및 로타바이러스 ｖｐ6 단백질
PCT/FI2011/050880 WO2012049366A1 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine
CA2814175A CA2814175C (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine
AU2011315405A AU2011315405B2 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus VP6 protein for use as combined vaccine
MX2013004159A MX352478B (es) 2010-10-14 2011-10-12 Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
BR112013009164A BR112013009164A2 (pt) 2010-10-14 2011-10-12 capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.
SG2013027974A SG189398A1 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine
RU2013121815/10A RU2013121815A (ru) 2010-10-14 2011-10-12 Капсид норовируса и белок vp6 ротавируса для использования в качестве комбинированной вакцины
CN201180049612.4A CN103260645B (zh) 2010-10-14 2011-10-12 用作联合疫苗的诺罗病毒壳体和轮状病毒vp6蛋白
JP2013533249A JP5902181B2 (ja) 2010-10-14 2011-10-12 混合ワクチンとして使用するためのノロウイルスカプシド及びロタウイルスｖｐ６タンパク質
TW100137092A TWI479022B (zh) 2010-10-14 2011-10-13 諾羅病毒衣殼與輪狀病毒ｖｐ６蛋白質做為組合疫苗的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20106067A FI122520B (fi) 2010-10-15 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
FI20106067 2010-10-15

Publications (2)

Publication Number Publication Date
FI20106067A0 FI20106067A0 (fi) 2010-10-15
FI122520B true FI122520B (fi) 2012-03-15

Family

ID=43064225

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20106067A FI122520B (fi) 2010-10-14 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena

Country Status (14)

Country Link
US (1) US8895015B2 (zh)
EP (1) EP2627353B1 (zh)
JP (1) JP5902181B2 (zh)
KR (1) KR101847472B1 (zh)
CN (1) CN103260645B (zh)
AU (1) AU2011315405B2 (zh)
BR (1) BR112013009164A2 (zh)
CA (1) CA2814175C (zh)
FI (1) FI122520B (zh)
MX (1) MX352478B (zh)
RU (1) RU2013121815A (zh)
SG (1) SG189398A1 (zh)
TW (1) TWI479022B (zh)
WO (1) WO2012049366A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150098681A (ko) 2007-03-14 2015-08-28 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
CN104024419A (zh) 2011-10-24 2014-09-03 丰田自动车株式会社 使用了重组酵母的乙醇的制造方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN103667199B (zh) * 2012-09-20 2019-01-22 厦门大学 体外制备轮状病毒双层类病毒颗粒的方法
WO2014153087A1 (en) 2013-03-14 2014-09-25 President And Fellows Of Harvard College Nanoparticle-based compositions
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
JP2018078806A (ja) * 2016-11-14 2018-05-24 東ソー株式会社 ノロウイルスｒｎａの検出方法
JP2020515531A (ja) 2017-03-28 2020-05-28 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
JP6879111B2 (ja) 2017-08-02 2021-06-02 トヨタ自動車株式会社 組換え酵母及びこれを用いたエタノールの製造方法
KR102038364B1 (ko) 2018-03-15 2019-10-30 전남대학교 산학협력단 소 로타바이러스 감염증 예방용 약독화 혼합생백신 조성물
WO2021140524A1 (en) 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
CN111265660B (zh) * 2020-01-19 2022-11-15 青岛明勤生物科技有限公司 一种通用型疫苗免疫增强剂
CN114316009B (zh) * 2020-09-29 2023-04-25 上海交通大学 一种能够结合多种病毒的蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
PT100090A (pt) 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
JP2000139473A (ja) * 1998-11-16 2000-05-23 Hokkaido Green Bio Kenkyusho:Kk ロタウイルス遺伝子を導入した遺伝子組換え植物、この遺伝子組換え植物に由来するロタウイルスのタンパク質及びこのロタウイルスのタンパク質に対する抗体
US20030166139A1 (en) 2001-07-20 2003-09-04 Choi Anthony H. Rotavirus VP6 subunit
US8277819B2 (en) * 2005-06-16 2012-10-02 Children's Hospital Medical Center Norovirus particle for use as an antiviral or vaccine
US8168202B2 (en) 2005-07-07 2012-05-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hexavalent bovine rotavirus reassortant composition designed for use in developing countries
EP2360175B1 (en) * 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
AU2008302276B2 (en) * 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
KR20150098681A (ko) * 2007-03-14 2015-08-28 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
AU2009237767A1 (en) * 2008-04-18 2009-10-22 Unilever Plc Compositions comprising antibodies or antibody fragments
WO2010006326A2 (en) * 2008-07-11 2010-01-14 Tufts University Methods and compositions for spore-based vaccines
WO2010144602A2 (en) 2009-06-09 2010-12-16 Children's Hospital Medical Center Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use

Also Published As

Publication number Publication date
RU2013121815A (ru) 2014-11-20
KR20140030100A (ko) 2014-03-11
US8895015B2 (en) 2014-11-25
JP5902181B2 (ja) 2016-04-13
EP2627353A1 (en) 2013-08-21
JP2013540773A (ja) 2013-11-07
CN103260645B (zh) 2016-03-16
EP2627353A4 (en) 2014-06-18
TWI479022B (zh) 2015-04-01
CN103260645A (zh) 2013-08-21
EP2627353B1 (en) 2017-11-29
FI20106067A0 (fi) 2010-10-15
MX2013004159A (es) 2013-11-04
KR101847472B1 (ko) 2018-04-11
AU2011315405B2 (en) 2016-09-22
AU2011315405A1 (en) 2013-05-23
TW201217530A (en) 2012-05-01
US20120093884A1 (en) 2012-04-19
BR112013009164A2 (pt) 2019-09-24
SG189398A1 (en) 2013-05-31
CA2814175C (en) 2019-11-05
CA2814175A1 (en) 2012-04-19
MX352478B (es) 2017-11-27
WO2012049366A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
FI122520B (fi) Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
RU2744193C2 (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
Li et al. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice
Perrin et al. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants
Zhang et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice
AU2020277165B2 (en) Feline calicivirus vaccine
Xu et al. Superior protection conferred by inactivated whole virus vaccine over subunit and DNA vaccines against salmonid alphavirus infection in Atlantic salmon (Salmo salar L.)
TW201920663A (zh) 免疫原性屈公病毒
CA2673355A1 (en) Antigenicity of infectious pancreatic necrosis virus vp2 sub-viral particles expressed in yeast
JP2008528504A (ja) ネコカリシウイルスに対する改良ワクチン
Crisci et al. Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant
CN108431214B (zh) 人轮状病毒g9p[6]毒株和作为疫苗的用途
Farnós et al. High-level expression and immunogenic properties of the recombinant rabbit hemorrhagic disease virus VP60 capsid protein obtained in Pichia pastoris
Rueda et al. Minor displacements in the insertion site provoke major differences in the induction of antibody responses by chimeric parvovirus-like particles
EP3583948A1 (en) Vaccines for the prevention of rabbit haemorrhagic disease
Farnós et al. Biochemical and structural characterization of RHDV capsid protein variants produced in Pichia pastoris: advantages for immunization strategies and vaccine implementation
WO2013030608A1 (en) Nanoparticle-based veterinary vaccine
RU2803427C1 (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
WO2022076977A1 (en) Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
Pourasgari et al. Intranasal immunization of mice with VP2 DNA of human rotavirus a induces cellular and humoral immunity
Khaled Calicivirus antigen engineering for possible vaccine development

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 122520

Country of ref document: FI

Kind code of ref document: B